In a previous molecular imaging study, HER2 receptor impaired accessibility by MUC4 in BC was shown to be appropriately assessed by in vivo molecular imaging using PET and Zirconium-89 radiolabeled trastuzumab (89Zr-Trastuzumab). The gene discussed is MUC4; the disease is breast cancer.